Wednesday, October 28
|
| 7:45 am - 7:00 pm |
iSBTc-FDA-NCI Workshop on Prognostic and Predictive Immunologic Biomarkers in Cancer
For more information on the Workshop, click here.
|
| |
Thursday, October 29
|
| 7:50 am - 8:00 am |
President's Welcome
Bernard A. Fox, PhD - Earle A. Chiles Research Institute |
| 8:00 am - 8:45 am |
Richard V. Smalley, MD Memorial Lectureship
The Biology and Therapy of Brain Metastasis
 Isaiah J. Fidler, DVM, PhD - MD Anderson Cancer Center
|
| 8:45 am - 11:30 am |
Plenary Session: Human Immunology
Co-Chairs: Jacques Banchereau, PhD - Baylor Institute for Immunology Research
Adrian Hayday, PhD - King's College London
|
| 8:45 am - 9:15 am |
Dendritic Cells as Therapeutic Vaccines in Cancer
Jacques Banchereau, PhD - Baylor Institute for Immunology Research |
|
| 9:15 am - 9:30 am |
Identification of Colon Cancer Associated Antigens which would be Key Therapeutic Targets in the Prevention of Disease Relapse or Progression
Elizabeth K. Broussard, MD - University of Washington Tumor Vaccine Group |
|
| 9:30 am - 10:00 am |
Harnessing Invariant NKT Cells to Abolish the Suppressive Activity of Myeloid Derived Suppressor Cells and Restore Melanoma Specific Immune Response
Vincenzo Cerundolo, MD, PhD - University of Oxford - Inst. of Molec. Medicine |
|
| 10:00 am - 10:15 am |
Identification of a Novel CD8+CD57+ T Cell Subset in Human Melanoma Exhibiting an Incompletely Differentiated CTL Phenotype
Richard Wu, BS - MD Anderson Cancer Center |
|
| 10:45 am - 11:00 am |
A Data Analysis Method for Identifying Autoantibody Biomarkers in Cancer Patients Following Immunotherapy
Janet Siebert, MD - CytoAnalytics |
|
| 11:00 am - 11:30 am |
γ8 T Cells-Agents of Tissue and Tumour Immune Surveillance
Adrian Hayday, PhD - King's College London |
|
| 11:30 am - 1:00 pm |
Lunch with Poster Viewing and Exhibits |
| 1:00 pm - 3:00 pm |
Plenary Session: Enhancing Cancer Vaccines / Combinations
Co-Chairs: Jeffrey Schlom, PhD - National Cancer Institute, NIH
Laurence Zitvogel, MD, PhD - Institute Gustave Roussy |
| 1:00 pm - 1:25 pm |
Enhancing Cancer Vaccines as Monotherapy and in Combination Therapies
Jeffrey Schlom, PhD - National Cancer Institute, NIH |
| 1:25 pm - 1:50 pm |
Defining the Role of TKIs in Reducing Immune Suppression While Improving T Cell Responsiveness and Efficacy of Immunotherapy for the Treatment of Tumors
James H. Finke, PhD - Cleveland Clinic Foundation |
| 1:50 pm - 2:05 pm |
Type-1 Dendritic Cell Vaccines in Combination With Poly-ICLC - Association Between Positive Tetramer Response and 6-Month Progression-Free Survival
Hideho Okada, MD, PhD - University of Pittsburgh Cancer Institute |
| 2:05 pm - 2:30pm |
IDO/IDO2 Inhibition: A New Strategy to Drive Immunotherapeutic Responses in Cancer by Reversing Tumoral Immune Tolerance
George C. Prendergast, PhD - Lankenau Institute for Medical Research |
| 2:30 pm - 3:00 pm |
How to Exploit the Immunogenicity of Chemotherapy or Radiotherapy Towards a Personalized Therapy of Cancer
Laurence Zitvogel, MD, PhD - Institute Gustave Roussy |
| 3:00 pm - 3:15 pm |
Break |
| 3:15 pm - 4:45 pm |
Concurrent Session I: Regulatory & Activated T Cell Subsets
Co-Chairs: Charles G. Drake, MD, PhD - Johns Hopkins University
Giorgio Trinchieri, MD - National Cancer Institute
|
| 3:15 pm - 3:30 pm |
CD81- A New Functional Marker for Tumor-induced Regulatory T Cells that Suppress Priming of Tumor-specific Effector T Cells in Reconstituted, Lymphopenic Hosts
Christian H. Poehlein, MD - Earle A. Chiles Research Institute |
| 3:30 pm - 3:55 pm |
Regulation of Tumor Immunity by NKT Cell Subsets
Masaki Terabe, PhD - National Cancer Institute |
| 3:55 pm - 4:20 pm |
IL-17 Secreting CD8 T Cells - Functional Plasticity and Potential Role in Tumor Immunity
Charles G. Drake, MD, PhD - Johns Hopkins University |
| 4:20 pm - 4:45 pm |
Interleukin-1 Role in Human TH17 Responses, Dendritic Cell Activation, and Epithelial Cell Transformation
Giorgio Trinchieri, MD - National Cancer Institute |
| 3:15 pm - 4:45 pm |
Concurrent Session II: Monoclonal Antibodies / Combinations
Co-Chairs: Glenn Dranoff, MD - Dana-Farber Cancer Instiute
Robert L. Ferris, MD, PhD - University of Pittsburgh Cancer Institute
|
| 3:15 pm - 3:35 pm |
FcγR Mediated Regulation of Adaptive Immunity: Implications for Antibody Therapies
Madhav Dhodapkar, MD - Yale University |
| 3:35 pm - 3:50 pm |
Synergy of Radiation and Immune Therapy in Tumor Eradication
Maria Grazia Ruocco, PhD - NYU - School of Medicine, Skirball Institute |
| 3:50 pm - 4:10 pm |
Enhancing Cancer Vaccines
Glenn Dranoff, MD - Dana-Farber Cancer Institute |
| 4:10 pm - 4:25 pm |
Antitumor Activity of Cytotoxic T-Lymphocyte Antigen-4 Blockade Alone or Combined with Paclitaxel, Etoposide, or Gemcitabine in Murine Models
Maria Jure-Kunkel, PhD - Bristol-Myers Squibb Company |
| 4:25 pm - 4:45 pm |
Immune Activation by Cetuximab Involves NK Cells, CTL and DC Against EGFR in Head and Neck Cancer
Robert L. Ferris, MD, PhD, FACS - University of Pittsburgh Cancer Institute |
| 5:00 pm - 5:30 pm |
iSBTc Membership Business Meeting |
| 5:30 pm - 7:00 pm |
Reception with Poster Viewing |
| |
|
Friday, October 30
|
8:00 am - 8:45 am
|
Keynote Address
T Cell Recognition and the Coming Golden Age of Human Immunology and Immunotherapy
Mark M. Davis, PhD - Howard Hughes Medical Institute / Stanford University School of Medicine
|
| 8:45 am - 11:30 am |
Plenary Session: Viral and Cellular Proteomic Targets
Co-Chairs: Lieping Chen, MD, PhD - Johns Hopkins University School of Medicine
Douglas R. Lowy, MD - National Cancer Institute, CCR
|
| 8:45 am - 9:15 am |
Current and Future Preventive HPV Vaccines
Douglas R. Lowy, MD - National Cancer Institute, CCR |
| 9:15 am - 9:45 am |
Therapeutic Strategies for Human Papillomavirus-Associated Cancers
Karl Münger, PhD - Brigham & Women's Hospital, Harvard Medical School |
| 9:45 am - 10:15 am |
Targets of Protective Tumor Immunity
Glenn Dranoff, MD - Dana-Farber Cancer Institute |
| 11:00 am - 11:15 am |
Definition of the Immunological Properties of Cancer Stem Cells Isolated from Human Glioblastoma
Cristina Maccalli, PhD - San Raffaele Foundation Scientific Institute |
| 11:15 am - 11:30 am |
Cell-Free EBV DNA is a Specific Biomarker for Tumour Burden in EBV-Associated Lymphomas
Kimberley Jones - Queensland Institute of Medical Research |
| 11:30 am - 1:00 pm |
Lunch with Poster Viewing and Exhibits |
| 1:00 pm - 2:20 pm |
iSBTc Presidential Session
Chair: Bernard A. Fox, PhD - Earle A. Chiles Research Institute |
| 1:00 pm - 1:20 pm |
T-Cell Delivery of Interleukin-12 to the Tumor Microenvironment Triggers Potent Endogenous Anti-Tumor Responses
Sid Kerkar, MD - National Cancer Institute, Center for Cancer Research |
| 1:20 pm - 1:40 pm |
Transduction of Tumor-Specific T Cells with the Gene Encoding CXCR2 Improves Migration to Tumor and In Vivo AntiTumor Immune Responses
Weiyi Peng, MD, PhD - University of Texas MD Anderson Cancer Center |
| 1:40 pm - 2:00 pm |
Eradication of Established CD19-Postive Leukemia Using a Single Injection of Chimeric Immunoreceptor Modified Lentiviral Transduced T Cells in a Xenograft Nog Mouse Model
David M. Barrett, MD, PhD - Children's Hospital of Philadelphia |
| 2:00 pm - 2:20 pm |
Cellular and Molecular Requirements for Rejection of B16 Melanoma in the Setting of Regulatory T Cell Depletion and Homeostatic Proliferation
Presented by Thomas F. Gajeski, MD, PhD on behalf of Justin P. Kline, MD- University of Chicago |
| 2:20 pm - 2:45 pm |
Break |
| 2:45 pm - 4:15 pm |
Concurrent Session I: Manipulation of the Tumor Microenvironment
Co-Chairs: James P. Allison, PhD - Memorial Sloan-Kettering Cancer Center
Dmitry I. Gabrilovich, MD, PhD - H. Lee Moffitt Cancer Center and Research Institute
|
| 2:45 pm - 3:15 pm |
Checkpoint Blockade in Tumor Immunotherapy: New Insights and Opportunities
James P. Allison, PhD - Memorial Sloan-Kettering Cancer Center |
| 3:15 pm - 3:30 pm |
Manipulation of the Tumor Microenvironment by CTLA-4 Blockade
Padmanee Sharma, MD, PhD - MD Anderson Cancer Center |
| 3:30 pm - 4:00 pm |
Myeloid-Derived Suppressor Cells and Tumor Microenvironment
Dmitry I. Gabrilovich, MD, PhD - H. Lee Moffitt Cancer Center and Research Institute |
| 4:00 pm - 4:15 pm |
Eosinophilic Granulocytes Modulate Tumor Microenvironment by Oxidizing Damage Associated Molecular Pattern Molecules Derived from Necrotic Tumor Cells
Ramin Lotfi, MD - University of Ulm, Institute for Transfusion Medicine |
| 2:45 pm - 4:15 pm |
Concurrent Session II: Targeted Therapeutics and Biological Therapy
Co-Chairs: Richard Jove, PhD - City of Hope Cancer Institute
David H. Munn, MD - Medical College of Georgia
|
| 2:45 pm - 3:15 pm |
Targeting Jak-Stat Signaling for Cancer Therapy
Richard Jove, PhD - City of Hope Cancer Institute |
| 3:15 pm - 3:45 pm |
Small-Molecule Inhibitors of the IDO Pathway as Immune Modulators
David H. Munn, MD - Medical College of Georgia |
| 3:45 pm - 4:00 pm |
Soluble, High Affinity T Cell Receptors as Cancer Therapeutics
Bent Jakobsen - Immunocore Ltd. |
| 4:00 pm - 4:15 pm |
Small Molecule Curcumin Analogs Induce Apoptosis in Human Melanoma Cells via STAT3 Inhibition but do not Alter the Cellular Response to Immunotherapeutic Cytokines
Gregory B. Lesinski, PhD - The Ohio State University |
| 4:30 pm - 5:00 pm |
Update: 2008 Workshop on Cancer & Inflammation: Promise for Biological Therapy
Michael T. Lotze, MD - University of Pittsburgh Cancer Institute |
| 5:00 pm - 5:30 pm |
Awards Presentation (View award recipients)
|
| 5:30 pm - 7:00 pm |
Presidential Reception with Poster Viewing |
| |
|
Saturday, October 31
|
| 8:00 am - 10:15 am |
Plenary Session: Adoptive Transfer
Co-Chairs: Carl H. June, MD - University of Pennsylvania
Steven A. Rosenberg, MD, PhD - National Cancer Institute
|
| 8:00 am - 8:30 am |
Cell Transfer Therapy for Patients with Metastatic Cancer
Steven A. Rosenberg, MD, PhD- National Cancer Institute |
| 8:30 am - 9:00 am |
What are the Functional and Phenotypic Qualities of Therapeutically Successful Anti-Tumor Cells?
Nicholas P. Restifo, MD - National Cancer Institute |
| 9:00 am - 9:15 am |
Programming Tumor-Reactive Effector Memory CD8+ T Cells In Vitro Obivates the Requirement for In Vivo Vaccination
Christopher A. Klebanoff, MD - National Institutes of Health, Center for Cancer Research |
| 9:15 am - 9:45 am |
Engineered T Cells for Cancer Therapy
Carl H. June, MD - University of Pennsylvania |
| 9:45 am - 10:15 am |
Adoptive Transfer of T Cells Genetically Modified Using the Sleeping Beauty System
Laurence J.N. Cooper, MD - MD Anderson Cancer Center |
| 10:15 am - 10:20 am |
Break |
| 10:20 am - 12:00 pm |
Hot Topic Symposium: Positive Immunotherapy Clinical Trial Outcomes
Co-Chairs: Thomas F. Gajewski, MD, PhD - University of Chicago
Drew M. Pardoll, MD, PhD - Johns Hopkins University School of Medicine
|
| 10:20 am - 10:25 am |
Welcome and Introductions
Thomas F. Gajewski, MD, PhD - University of Chicago |
| 10:25 am - 10:45 am |
Therapeutic Vaccines for Lymphoma: A Tale of Bench to Beside Translation
Larry W. Kwak, MD, PhD - MD Anderson Cancer Center |
| 10:45 am - 11:05 am |
A Phase III Multi-Institutional Randomized Study of Immunization with the gp 100:209-217 (210M) Peptide Followed by High Dose IL-2 vs. High Dose IL-2 Alone in Patients with Metastatic Melanoma
Doug J. Schwartzentruber, MD, FACS - Goshen Center for Cancer Care |
| 11:05 am - 11:25 am |
Development History of Sipuleucel-T: Progress of an Active Immunotherapy for Prostate Cancer
David L. Urdal, PhD - Dendreon Corporation |
| 11:25 am - 11:35 am |
NY-ESO-1 Specific Responses in Patients with Advanced Prostate Cancer Treated wtih Ipilimumab
Jianda Yuan, MD, PhD - Memorial Sloan-Kettering Cancer Center |
| 11:35 am - 11:45 am |
Circulating Regulatory T Cell Function and Overall Survival in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Poxviral-based Vaccine
Matteo Vergati, MD - National Cancer Institute, Center for Cancer Research |
| 11:45 am - 12:00 pm |
Audience Discussion
Moderator: Drew M. Pardoll, MD, PhD - Johns Hopkins School of Medicine |
| |
|
